Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06138639 · ClinicalTrials.gov registry record · Phase 1

A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

A Phase 1 study of Duchenne Muscular Dystrophy, sponsored by Solid Biosciences.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
15
Study locations

NCT06138639: Recruiting Phase 1 study of Duchenne Muscular Dystrophy, sponsored by Solid Biosciences.

NCT06138639 is a Phase 1 study of Duchenne Muscular Dystrophy that is actively recruiting participants, run by Solid Biosciences. The registered enrollment target is 60 participants, below the 411-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (85% lower). The trial reports 15 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06138639, a Phase 1 study of Duchenne Muscular Dystrophy, is actively recruiting participants, sponsored by Solid Biosciences.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
15
Study locations

Study Summary

This is a multicenter, open-label, non-randomized study to investigate the safety, tolerability, and efficacy of a single intravenous (IV) infusion of SGT-003 in participants with Duchenne muscular dystrophy. There will be 5 cohorts in this study. Cohort 1 will include participants 4 to \< 7 years of age. Cohort 2 will include participants 7 to \< 12 years of age. Cohort 3 will include participants 0 to \< 4 years of age. Cohort 4 will include participants 12 to \< 18 years of age. Cohort 5 will include participants 10 to \< 18 years of age. Initiation of participant enrollment in Cohorts 4 and 5 will be subject to the accrual of safety and efficacy data from Cohorts 1-3. All participants will receive SGT-003 and will be enrolled in the study for 5 total years for long-term follow up.

Conditions Studied

Duchenne Muscular Dystrophy

Interventions

  • GENETIC SGT-003

Study Locations (15)

California

  • University of California, Los Angeles Medical Center - Los Angeles
  • University of California, Davis - Sacramento
  • University of California - San Diego

Other

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome
  • Great Ormond Street Hospital - London

Arkansas

  • Arkansas Children's Hospital - Little Rock

Georgia

  • Rare Disease Research - Atlanta

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago

Missouri

  • Washington University in St. Louis - St Louis

Ohio

  • Nationwide Children's Hospital - Columbus

Oregon

  • Oregon Health and Sciences University - Portland

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-05-06
Est. Completion 2031-05-06
Phase Phase 1
Solid Biosciences

6 total trials

What NCT06138639 shows while recruiting

NCT06138639 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 411-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which SGT-003 is the first listed.

NCT06138639 lists 15 locations in 12 states (California, Other, Arkansas).

Frequently Asked Questions

What is clinical trial NCT06138639 about?

NCT06138639 is a clinical study titled "A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)". This is a multicenter, open-label, non-randomized study to investigate the safety, tolerability, and efficacy of a single intravenous (IV) infusion of SGT-003 in participants with Duchenne muscular dystrophy. There will be 5 cohorts in this study. Cohort 1 will include participants 4 to \< 7 years o...

What is the current status of trial NCT06138639?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2024-05-06. Estimated completion is 2031-05-06.

What conditions does trial NCT06138639 study?

This clinical trial studies the following conditions: Duchenne Muscular Dystrophy.

What interventions are being tested in trial NCT06138639?

The interventions under investigation include: SGT-003 (GENETIC).

Who is sponsoring clinical trial NCT06138639?

This trial is sponsored by Solid Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06138639 being conducted?

This trial has 15 study locations across Arkansas, California, Georgia, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Duchenne Muscular Dystrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06138639's enrollment target sits among peer trials

60 21st of 48 higher than 28 of 48 other Duchenne Muscular Dystrophy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Duchenne Muscular Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06138639

Source: ClinicalTrials.gov NCT06138639, the US trial registry maintained by the National Library of Medicine. NCT06138639 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.